Status:
ACTIVE_NOT_RECRUITING
Restoration of Central Vision With the PRIMA System in Patients With Atrophic AMD
Lead Sponsor:
Science Corporation
Conditions:
Geographic Atrophy
Eligibility:
All Genders
60+ years
Phase:
NA
Brief Summary
The objective of this study is to evaluate the efficacy and safety of the PRIMA System in patients with atrophic AMD. Eligible subjects will be implanted with the PRIMA Implant. The subjects will be a...
Eligibility Criteria
Inclusion
- Is 60 years or older at the date of inclusion;
- Has a confirmed diagnosis of geographic atrophy due to AMD in both eyes;
- The study eye has best corrected visual acuity of logMAR 1.2 (20/320) or worse as measured by ETDRS test;
- Has an atrophic patch in the study eye including the fovea of at least the implant size (\>4.5 mm2 and \>2.4 mm in minimum diameter);
- Understands the constraints of the study and accepts to present for all scheduled follow-up visits;
- Patient signed informed consent
Exclusion
- Has cataract in the study eye (with LOCS III scale NO, NC, C or P\>1); (these patients will be asked to have cataract surgery performed prior to enrollment; all other patients will get IOL replacement during the PRIMA implantation);
- Underwent intra ocular lens implantation in the study eye within the last month ;
- Has a highly myopic study eye (\>26 mm AP);
- Has a highly hyperopic study eye (\<20 mm AP);
- Has no light perception in either eye;
- Has a history of documented choroidal neovascularization in either eye;
- Has any signs of exudative AMD including exudative AMD with detachment of retinal pigment epithelium in the central visual field of the study eye;
- Has an implanted telescope in one eye;
- Has a black IOL in the study eye;
- Has any disease (other than study allowed diseases) or condition that affects retinal function of the study eye or the visual system (e.g., central retinal artery/vein occlusion, end-stage diabetic retinopathy, Proliferative Diabetic Retinopathy (PDR), diabetic macular edema (DME), severe Non-Proliferative Diabetic Retinopathy (NPDR), retinal detachment, infectious or inflammatory retinal disease, severe glaucoma, optic neuropathy, etc.) ;
- Has any disease or condition that prevents adequate examination (including OCT) of the study eye including, but not limited to media opacities that cannot be resolved prior to implantation. Note, that this criterion is also important for the function of the implant;
- Has a corneal endothelial cell count of less than 1000 cells/mm² in the study eye;
- Suffers from nystagmus or other ocular motility disorders;
- Has any disease or condition that precludes the understanding or communication of the informed consent, study requirements or test protocols (e.g., deafness, severe multiple sclerosis, amyotrophic lateral sclerosis, severe neuritis, etc.);
- Has epileptic seizures;
- Has a known sensitivity to the contact materials of the implant (iridium oxide, silicon-carbide and titanium);
- Has a known allergy to anesthetic drugs;
- Presents with hypotonia in the study eye (\<8 mmHg);
- Presents with hypertonia in the study eye (\>23 mmHg with treatment);
- Has active cancer or a history of intraocular, optic nerve or brain cancer and metastasis;
- Is an immune-suppressed subject (e.g., due to HIV positive diagnosis, etc.);
- Is a known carrier of multi-resistant microorganisms;
- Is receiving anticoagulation therapy that cannot be adapted to allow eye surgery;
- Is participating in another investigational drug or device study that may interfere with the PRIMAvera study;
- Has a history of chronic or recurrent infection or inflammation that would preclude participation in the study;
- Has significant recurrent or chronic inflammations or infections. Specifically, patients with the following disorders are excluded:
- Severe chronic and consuming diseases that frequently associated with infection (e.g. Crohn disease, Whipple's disease);
- Active inflammation in the area of the eye (e.g. herpes of cornea and/or conjunctiva, recurrent blepharoconjunctivitis, hordeolum, chalazion);
- Has a severe psychological disorder;
- Does not have the mental capacity to legally sign the informed consent;
- Has severe renal, cardiac, hepatic, etc. organ diseases (ASA IV or worse);
- Has head dimensions that are incompatible with the PRIMA Glasses;
- Has a refraction of study eye higher than + 4 dpt or lower than - 4 dpt for patients with IOL (there is no refraction criteria for phakic patients, since they get an IOL during PRIMA implantation);
- Has too high and/or unrealistic expectations (e.g., believes that a benefit is guaranteed or expects normal vision after surgery).
- The following additional exclusion criteria are applicable for French subjects:
- Is a protected person per French law (e.g. is under guardianship, person deprived of their liberty);
- Is not affiliated to a mandatory social security program (health insurance).
Key Trial Info
Start Date :
November 24 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 1 2028
Estimated Enrollment :
38 Patients enrolled
Trial Details
Trial ID
NCT04676854
Start Date
November 24 2020
End Date
February 1 2028
Last Update
November 29 2024
Active Locations (21)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpital Pellegrin
Bordeaux, France, 33000
2
Centre hospitalier intercommunal de Créteil - Service Ophtalmologie
Créteil, France, 94000
3
Hôpital de la Croix-Rousse CHU de LYON
Lyon, France, 69004
4
Centre Monticelli Paradis
Marseille, France, 13008